You are here

Article Text

Article menu

Download PDFPDF

Poster Presentations
P73 Predictors of flares after glucocorticoid discontinuation in remitted patients with SLE
  1. Filippo Vesentini1,
  2. Federico Arru1,
  3. Rosanna Somma2,
  4. Noemi Merra1,
  5. Cristina Cadore1,
  6. Ilenia Gennaio1,
  7. Claudio Cruciani1,
  8. Luca Iaccarino1,
  9. Margherita Zen1 and
  10. Andrea Doria1
  1. 1Rheumatology Unit, DIMED, University of Padua, Padua, Italy
  2. 2Rheumatology Unit, University of Verona, Verona, Italy

Abstract

Objective Data on the safety and feasibility of the discontinuation glucocorticoids (GCs) in remitted patients with SLE are scanty and controversial results have been published. Our aim was to assess the predictors of flares after GCs discontinuation in a large cohort of prospectively followed patients.

Methods Patients diagnosed after 1980 and followed-up until 2023 who achieved remission lasting at least 6 months at least once during their disease course were included. Remission was defined as clinical SLEDAI-2K=0 on a stable immunosuppressive and/or antimalarial therapy and/or prednisone ≤5 mg/day. Flares were defined as any increase in clinical SLEDAI-2K>0 or the need for changes in SLE medications. Remitted patients who flared after discontinuing GCs were compared with patients who did not flare. Logistic regression was used to identify predictors of flare and Cox-regression to identify predictors of flare-free survival.

Results Prospectively collected data from 484 patients who achieved remission at least once during follow-up were retrospectively analysed. Three-hundred-eighty patients achieved remission off-GCs and were analysed. During a mean observational time of 87 (±76) months, 48 flares were observed, meaning an annual flare rate of1.65 flare/100 patients/year. At multivariate logistic regression analysis, predictors of flares after GC withdrawal were low C3 levels (OR 0.007, CI 95% 0.00–0.188, p=0.007), arthritis (3.108, 1.096–8.811, p=0.033), leukopenia (2.146, 1.030–4.472, p=0.041), vasculitis (2.650, 1.037–6.773,p =0.042), and remission duration (0.987, 0.980–0.995, p<0.001). By Cox regression analysis, predictors of shorter flare-free remission were thrombocytopenia (HR 2.446, CI 95% 1.106–5.410, p=0.027), vasculitis (3.033, 1.262–7.432, p=0.013), disease duration (0.943, 0.892–0.998, p=0.054), and positive anti-U1RNP (1.973, 0.988–3.940, p=0.054).

Conclusion According to our results, remission off-GCs is an achievable outcome in SLE, especially in patients without serological activity and in those with stable remission.

http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ .

https://doi.org/10.1136/lupus-2024-el.127

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.